Article info

Download PDFPDF

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Authors

  1. a 9804422000 Asim.Amin{at}carolinashealthcare.org
  2. b elizabeth.plimack{at}fccc.edu
  3. c marc.ernstoff{at}RoswellPark.org
  4. d lionel.d.lewis{at}dartmouth.edu
  5. e tbauer{at}tnonc.com
  6. f dmcdermo{at}bidmc.harvard.edu
  7. g carducci{at}jhmi.edu
  8. h ckollmannsberger{at}bccancer.bc.ca
  9. i rinib2{at}ccf.org
  10. j daniel.heng{at}albertahealthservices.ca
  11. k jennifer.knox{at}uhn.on.ca
  12. l vossm{at}mskcc.org
  13. m jennifer.spratlin{at}albertahealthservices.ca
  14. n elmer.berghorn{at}bms.com
  15. o lingfengy{at}gmail.com
  16. p Hans.Hammers{at}UTSouthWestern.edu
View Full Text

Citation

Amin A, Plimack ER, Ernstoff MS, et al
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Publication history

  • Received July 5, 2018
  • Accepted September 26, 2018
  • First published October 22, 2018.
Online issue publication 
October 22, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.